

**Candida glabrata, Strain DSY562**

**Catalog No. NR-51685**

**Product Description:**

*Candida glabrata* (*C. glabrata*), strain DSY562 was isolated in 1995 from a patient with acquired immunodeficiency syndrome and oropharyngeal candidiasis. NR-51685 was produced by inoculation of the deposited material onto Yeast Mold agar, which was grown for 3 days at 25°C in an aerobic atmosphere. The agar growth was harvested with 20% glycerol to produce this lot.

**Lot: 70027686**

**Manufacturing Date: 02AUG2019**

TEST	SPECIFICATIONS	RESULTS
<b>Phenotypic Analysis</b> Cellular morphology <sup>1</sup>  Colony morphology <sup>1</sup> Biochemical Tests VITEK® 2 (YST card)	Report results  Report results  <i>C. glabrata</i> (≥ 89%)	Ovoid to round; in singles and in clumps; no pseudohyphae Butyrous, smooth and cream  <i>C. glabrata</i> (98%)
<b>Antibiotic Susceptibility Profile</b> Etest® antibiotic test strips <sup>2,3</sup> Amphotericin B Fluconazole  Voriconazole	Report results Report results  Report results	Susceptible (0.75 µg/mL) Susceptible-dose dependent (24 µg/mL) <sup>4</sup> Susceptible (1.5 µg/mL) <sup>5</sup>
<b>Genotypic Analysis</b> Sequencing of partial 18S ribosomal RNA (rRNA) gene, internal transcribed spacer (ITS) 1, 5.8S rRNA gene, ITS 2, partial 26S rRNA (~ 840 base pairs) Sequencing of 28S rRNA gene (~ 603 base pairs)	≥ 99% sequence identity to <i>C. glabrata</i> , strain DSY562 (GenBank: MVOE01000012.1) ≥ 99% sequence identity to <i>C. glabrata</i> , strain DSY562 (GenBank: MVOE01000012.1)	100% sequence identity to <i>C. glabrata</i> , strain DSY562 (GenBank: MVOE01000012.1) <sup>6</sup> 100% sequence identity to <i>C. glabrata</i> , strain DSY562 (GenBank: MVOE01000012.1) <sup>6</sup>
<b>Purity<sup>7</sup></b> Nutrient broth with 0.1% Yeast Extract at 25°C Nutrient broth with 0.1% Yeast Extract at 37°C	No bacterial growth No bacterial growth	No bacterial growth No bacterial growth
<b>Viability (post-freeze)<sup>8</sup></b>	Growth	Growth

<sup>1</sup>4 days at 25°C in an aerobic atmosphere on Yeast Mold agar

<sup>2</sup>2 days at 37°C in an aerobic atmosphere on RPMI 1640 agar containing MOPS buffer and 2% glucose (Remel™ R04067)

<sup>3</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: Song, Y. B., et al. "Antifungal Susceptibility Testing with Etest for *Candida* Species Isolated from Patients with Oral Candidiasis." *Ann. Dermatol.* 27 (2015): 715-720. PubMed: 26719641.

<sup>4</sup>Two MICs were observed for fluconazole (16 µg/mL and 24 µg/mL) under identical test conditions. The highest MIC is being reported as the test result.

<sup>5</sup>Two MICs were observed for voriconazole (0.75 µg/mL and 1.5 µg/mL) under identical test conditions. The highest MIC is being reported as the test result.

<sup>6</sup>Also consistent with *C. albicans*

<sup>7</sup>Clarity of broth was determined by visual inspection after 3 days in an aerobic atmosphere.

<sup>8</sup>3 days at 25°C in an aerobic atmosphere on Yeast Mold agar

/Heather Couch/

Heather Couch

14 FEB 2020

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

